echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Neurology: Neurofascin-155 immunoglobulin subtypes, clinicopathological associations and neurological outcomes

    Neurology: Neurofascin-155 immunoglobulin subtypes, clinicopathological associations and neurological outcomes

    • Last Update: 2021-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Neurofascin-155 (NF155) autoantibody is one of the most common nodular and paranodular antibodies, accounting for 4% to 18% of all chronic demyelinating polyneuropathy (CIDP) cases
    .


    Despite the increasing application of these antibodies in clinical practice, research to evaluate long-term results and histopathological characteristics is limited


    With this, Shahar Shelly and others at the Mayo Clinic explored the frequency of NF155 autoantibodies in a large cohort of demyelinating neuropathy
    .


    And evaluate the phenotype and histopathological specificity, as well as the difference in results between NF155-IgG4 seropositive, NF155 pan-IgG and NF155-IgM seropositive cases


    Method
    .


    In this study, NF155-IgG4, NF155-IgG, and NF155-IgM autoantibodies were tested in the serum of neuropathic patients who attended the Mayo Clinic


    They found 32 NF155 patients (25 NF155-IgG positive [20 NF155-IgG4 positive] and 7 NF155-IgM seropositive)
    .


    Patients with NF155-IgG4 seropositive have clinically more distal muscle weakness than proximal muscle weakness, positive sensory symptoms (tingling, asymmetric paralysis, neuropathic pain) and gait ataxia


    Electrical diagnostic tests (EDX) show demyelinating polyneuropathy (19 / 20.
    95%)
    .


    Autonomic nerve involvement occurred in 45% of patients (9 patients, median CASS score 3.


    Diagnostic immunity

    NF155-IgG positive NF155-IgG4 negative (NF155-IgG positive) and NF155-IgM positive patients are phenotypically different from NF155-IgG4 seropositive patients
    .

    NF155-IgG positive NF155-IgG4 negative (NF155-IgG positive) and NF155-IgM positive patients are phenotypically different from NF155-IgG4 seropositive patients
    .


    Compared with MAG-IgM neuropathy, sensory ataxia, neuropathic pain, cerebellar dysfunction, and root/plexus MRI abnormalities are significantly more common in NF155-IgG4-positive patients
    .

    Compared with NF155-IgG4 positive cases, the chronic immunosensory polyneuropathy (CISP)/CISP-plus phenotype is more common in Contactin-1 neuropathy
    .

    Compared with MAG-IgM seropositive cases, NF155-IgG4 positive cases responded well to immunotherapy.
    Compared with contactin-1 IgG, distally acquired demyelinating symmetric neuropathy (P<0.
    001) had better long-term clinical efficacy.
    Good (P=0.
    04)
    .

    The important significance of this study lies in the discovery of long-term follow-up and clinical results of NF155-IgG4 patients
    .


    Patients with NF155-IgG4 (rather than IgM or IgG) have unique clinical-electrodiagnostic characteristics


    Patients with NF155-IgG4 (instead of IgM or IgG) have unique clinical-electrodiagnostic characteristics

    Original source:
    Shelly S, Klein C, Dyck PJB, et al.


    Neurofascin-155 Immunoglobulin Subtypes: Clinicopathologic Associations and Neurologic Outcomes.
     Neurology.
    Published online October 11, 2021:10.


    Neurofascin-155 Immunoglobulin Subtypes: Clinicopathologic Associations and Neurologic Outcomes.

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.